Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics’ Dual-Acting Factor XI/XIa Inhibitor Abelacimab
June 08, 2023 11:10 ET
|
Anthos Therapeutics
Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated Approximately 63% of Cancer Patients in China...
New Assessment Scale to Measure Adherence to Oral Anticoagulants Based on Impact of Patient Relevant Bleeding in Atrial Fibrillation Presented at ISPOR 2023
May 09, 2023 09:45 ET
|
Anthos Therapeutics
Anticoagulant Bleeding Burden Adherence Confidence Assessment Scale [ABBA-CAS] Created to Better Address an Important Treatment Gap in the Management of Atrial Fibrillation (AF) and Bring Patient...
New Assessment Scale to Capture Patient Relevant Bleeding to be Presented at ISPOR 2023
May 05, 2023 08:00 ET
|
Anthos Therapeutics
Additional presentation spotlights GARDENIA registry design in patientswith atrial fibrillation and atrial flutter Early Cost-Effectiveness Modeling for Patients with Atrial Fibrillation and Cancer...
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
January 03, 2023 08:00 ET
|
Anthos Therapeutics
FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third Phase 3...
Anthos Therapeutics Announces that Abelacimab Has Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
September 08, 2022 08:00 ET
|
Anthos Therapeutics
This is the second Fast Track designation issued by the FDA for abelacimab Abelacimab is a dual-acting, once-monthly, fully human monoclonal antibody targeting both Factor XI and Factor XIa with high...
Anthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, Abelacimab
August 25, 2022 08:00 ET
|
Anthos Therapeutics
Abelacimab is the only Factor XI inhibitor currently being evaluated in Phase 3 trials The MAGNOLIA study will compare abelacimab against the current standard of care for VTE in cancer associated...